ISRCTN76294777终止2 期
A phase 2b multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of JNJ-81241459 for the treatment of participants with moderate to severe plaque psoriasis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Be =18 years of age at screening, inclusive
- •2. Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
- •3. Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
- •4. Total Psoriasis area and severity index (PASI) >=12 at screening and baseline
- •5. Total Investigator global assessment (IGA) >=3 at screening and baseline
- •6. Candidate for phototherapy or systemic treatment for plaque Psoriasis
排除标准
- •1. Nonplaque form of psoriasis (eg, erythrodermic, guttate, or pustular)
- •2. Current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- •3. Known allergies, hypersensitivity, or intolerance to JNJ-81241459 or its excipients (refer to the JNJ-81241459 IB)
- •4. Previously received JNJ-81241459
- •5. Experienced primary efficacy failure (no response within 12 weeks) or a clinical adverse event related to agents directly targeting interleukin 17 receptor (IL-17)
研究者
相似试验
进行中（未招募）
1 期
A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus diseaseEUCTR2018-001808-11-BGIdorsia Pharmaceuticals Ltd427
进行中（未招募）
1 期
A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus diseaseEUCTR2018-001808-11-ITIDORSIA PHARMACEUTICALS LTD500
进行中（未招募）
1 期
A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus diseaseEUCTR2018-001808-11-FRIdorsia Pharmaceuticals Ltd500
进行中（未招募）
1 期
A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus diseaseEUCTR2018-001808-11-GBIdorsia Pharmaceuticals Ltd325
进行中（未招募）
1 期
A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus diseaseEUCTR2018-001808-11-ESIdorsia Pharmaceuticals Ltd500